I remain skeptical for the reasons mentioned in #msg-130823331 and others. CAT makes heavy exclusions to non-GAAP EPS from "restructuring" costs, which are actually a recurring item for most cyclical companies. Moreover, CAT's performance in China (cited by Barron's in the excerpt above) has been up and down and up and down over the past decade or so; it seems unrealistic to think it will go straight up.
That’s a very substantial 9% increase at the midpoints of the ranges. (You would think investors could figure out that a range of $42-44B has a midpoint of $43B, LOL.)
Due to CAT’s high operating leverage, the ~9% revenue boost in the latest guidance (compared to the old guidance) produces a huge increase in GAAP and non-GAAP EPS. However, note that the large restructuring costs are excluded from non-GAAP EPS—something that I have questioned in previous posts on this board given the cyclical nature of the business.